ロード中...
Absence of Novel CYP4F2 and VKORC1 Coding Region DNA Variants in Patients Requiring High Warfarin Doses
OBJECTIVE: Warfarin is an FDA-approved oral anticoagulant for long-term prevention of thromboembolism. Substantial inter-individual variation in dosing requirements and the narrow therapeutic index of this widely-prescribed drug make safe initiation and dose stabilization challenging. Single nucleot...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Marshfield Clinic
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3251364/ https://ncbi.nlm.nih.gov/pubmed/21562135 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3121/cmr.2011.951 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|